Gut microbiota: A potential therapeutic target for management of diabetic retinopathy?

Rosa Elvira Alarcón Yempén,Raphaelly Venzel,Maria Clara Paulino Campos,Larissa Pessoa de Oliveira,Rodrigo Vasquez Dan Lins,André Moreira Pessoni,Gustavo Bernardes Fanaro,Anderson de Oliveira Souza,Karin da Costa Calaza,José Luiz de Brito Alves,Marinaldo Pacífico Cavalcanti-Neto
DOI: https://doi.org/10.1016/j.lfs.2021.120060
IF: 6.78
2021-12-01
Life Sciences
Abstract:Diabetic Retinopathy (DR) is one of the main complications of Diabetes Mellitus (DM), drastically impacting individuals of working age over the years, being one of the main causes of blindness in the world. The existing therapies for its treatment consist of measures that aim only to alleviate the existing clinical signs, associated with the microvasculature. These treatments are limited only to the advanced stages and not to the preclinical ones. In response to a treatment with little resolution and limited for many patients with DM, investigations of alternative therapies that make possible the improvement of the glycemic parameters and the quality of life of subjects with DR, become extremely necessary. Recent evidence has shown that deregulation of the microbiota (dysbiosis) can lead to low-grade, local and systemic inflammation, directly impacting the development of DM and its microvascular complications, including DR, in an axis called the intestine-retina. In this regard, the present review seeks to comprehensively describe the biochemical pathways involved in DR as well as the association of the modulation of these mechanisms by the intestinal microbiota, since direct changes in the microbiota can have a drastic impact on various physiological processes. Finally, emphasize the strong potential for modulation of the gut-retina axis, as therapeutic and prophylactic target for the treatment of DR.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?